Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy - A pilot study from the VErA cohort

Joint Bone Spine

Volumn 79, Issue 6, 2012, Pages 574-580

  Lanfant Weybel, Karine ^a   Michot, Chantal ^b   Daveau, Romain ^a   Milliez, Pierre Yves ^b   Auquit Auckbur, Isabelle ^b   Fardellone, Patrice ^c   Brazier, Michel ^c   Mejjad, Othmane ^a   Daragon, Alain ^a   Krzanowska, Kataryna ^a   Jouen, Fabienne ^b   Tron, François ^b   Le Loarer, François ^b   Le Loët, Xavier ^a   Vittecoq, Olivier ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

CD20; Prognosis; Rheumatoid arthritis; Structural damage; Synovial biomarkers; Very early arthritis

Indexed keywords

C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CD163 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLUCOCORTICOID; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN BCL 2; RHEUMATOID FACTOR; VASCULOTROPIN;

ADULT; AGED; ARTHRITIS; ARTICLE; B LYMPHOCYTE ACTIVATION; BONE EROSION; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; JOINT BIOPSY; MALE; METACARPOPHALANGEAL JOINT; MONOTHERAPY; PILOT STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOGRAPHY; SYNOVIUM;

ADULT; AGED; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOPSY; BONE RESORPTION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; METACARPOPHALANGEAL JOINT; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RANK LIGAND; SYNOVIAL MEMBRANE; TREATMENT OUTCOME;

EID: 84870660290     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.11.006     Document Type: Article

References (35)

1. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
2. Saraux A., Devauchelle-Pensec V., Engerran L., et al. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey. J Rheumatol 2006, 33:1258-1265.
3. Pap T., Franz J.K., Hummel K.M., et al. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000, 2:59-64.
4. Firestein G.S., Echeverri F., Yeo M., et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997, 94:10895-10900.
5. Pettit A.R., Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis?. Immunol Cell Biol 1999, 77:420-427.
6. Falgarone G., Jaen O., Boissier M.C. Role of innate immunity in rheumatoid arthritis. Joint Bone Spine 2005, 72:17-25.
7. Clavel G., Bessis N., Boissier M.C. Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine 2003, 70:321-326.
8. Jalkanen S., Steere A., Fox R.I., et al. A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium. Science 1986, 233:556-558.
9. Bresnihan B., Alvaro-Gracia J.M., Cobby M., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
10. Smeets T.J., Kraan M.C., Van Loon M.E., et al. Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155-2162.
11. Okada Y., Morodomi T., Enghild J.J., et al. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem 1990, 194:721-730.
12. Hofbauer L.C., Heufelder A.E. Role of receptor activator of nuclear factor-κB-ligand and osteoprotegerin in bone cell biology. J Mol Med 2001, 79:243-253.
13. Combe B., Dougados M., Goupille P., et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001, 44:1736-1743.
14. Lindqvist E., Eberhardt K., Bendtzen K., et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005, 64:196-201.
15. Meyer O., Nicaise-Roland P., Santos M.D., et al. Serial determination of cyclic citrullinated peptide autoantibodies predicted 5-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006, 8:R40.
16. Machold K.P., Stamm T.A., Nell V.P., et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007, 46:342-349.
17. Cunnane G., Fitzgerald O., Beeton C., et al. Early joint erosions and serum levels of metalloproteinase 1, metalloproteinase 3 and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 2001, 44:2263-2274.
18. Green M.J., Gough A.K., Devlin J., et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 2003, 42:83-88.
19. Tchetverikov I., Lard L.R., DeGroot J., et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003, 62:1094-1099.
20. Geusens P.P., Landewé R.B., Garnero P., et al. The ratio of circulating osteoprotegerin to RANK-L in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006, 54:1772-1777.
21. Garnero P., Gineyts E., Christgau S., et al. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46:21-30.
22. Goëb V., Dieudé P., Daveau R., et al. Contribution of PTPN22 1858T, TNFR2 196R and HLA-shared epitope alleles and rheumatoid factor and anti-citrullinated protein antibodies to early rheumatoid arthritis diagnosis. Rheumatology 2008, 47:1208-1212.
23. Bresnihan B., Tak P.P. Synovial tissue analysis in rheumatoid arthritis. Baillière's Clin Rheumatol 1999, 13:645-659.
24. van der Heijde D.M. How to read radiographs according to the Sharp/van der Heidje method. J Rheumatol 1999, 26:743-745.
25. R Development Core Team R: a language and environment for statistical computing 2008, R Foundation for Statistical Computing, Vienna, Austria.
26. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
27. Cunnane G., FitzGerald O., Hummel K.M., et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001, 44:1744-1753.
28. Fonseca J.E., Corte-Dias N., Francisco A., et al. Inflammatory cell infiltrate and RANK-L/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 2005, 23:185-192.
29. Cañete J.D., Celis R., Vasquez I., et al. RANK-L, OPG, Tie-2 and IL-18 synovial expression in early arthritis and its relationship with joint damage development [abstract]. Arthritis Rheum 2006, 54:s600.
30. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomised, double-blind, placebo-controlled, phase 3 trial evaluating primary efficacy and safety at 24 weeks. Arthritis Rheum 2006, 54:2793-2806.
31. Tak P.P., Rigby W.F., Rubbert-Roth A., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011, 70:39-46.
32. Matsumoto I., Staub A., Benoist C. Arthritis provoked by inked T- and B-cell recognition of a glycolytic enzyme. Science 1999, 286:1732-1735.
33. Gottenberg J.E., Miceli-Richard C., Ducot B., et al. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009, 11:R114.
34. Sibilia J., Gottenberg J.E., Mariette X. Rituximab: a new alternative in rheumatoid arthritis. Joint Bone Spine 2008, 75:526-532.
35. Yamanaka H., Matsuda Y., Tanaka M., et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000, 43:852-858.